Ainara Salazar-Villacorta

Ainara Salazar-Villacorta

Auto-generated profile, based on publicly available information

Ainara Salazar-Villacorta

Department of Neuromuscular Disorders UCL Queen Square Institute of Neurology London UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Brain
Verified
Journal Article
Closed access
VQVicente Quiroz
Vicente Quiroz
JAJulian E Alecu
Julian E Alecu
UZUmar Zubair
Umar Zubair
KBKaterina Bernardi
Katerina Bernardi
ZZZainab Zaman
Zainab Zaman
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari
Epilepsy-dyskinesia syndromes (EDS) are a complex group of neurogenetic disorders characterized by the co-occurrence of epilepsy and movement disorders. Despite their increasing clinical recognition, the molecular and clinical spectrum of EDS remains poorly understood. While numerous genetic aetiologies have been implicated, systematic characterization across diverse populations is lacking. This study aimed to delineate the molecular and clinical landscape of EDS in a large, multinational cohort, focusing on movement disorder phenomenologies, genotype-phenotype correlations, and treatment responses. We conducted a multicentre, cross-sectional study involving 609 patients with childhood-onset movement disorders associated with pathogenic variants in 105 predefined genes. Clinical data were collected from over 30 centres across 25 countries using a standardized survey, capturing movement disorder phenomenologies, seizure types, developmental trajectories, motor function and treatment outcomes. We classified EDS-associated genes into biologically meaningful groups by performing unsupervised clustering, which integrated protein-protein interactions and functional data. Genotype-phenotype correlations were assessed using a one-versus-remainder approach to quantify differential enrichment of clinical manifestations and treatment responses. Pathogenic variants were identified in 74 of the 105 predefined genes, with 12 genes accounting for two-thirds of cases. The most frequently reported genes were MECP2, ATP1A3, and GNAO1. Data-driven gene cluster analysis identified 12 functional groups, mapping EDS to relevant biological pathways and informing genotype-phenotype analyses. Dystonia (34.2%), stereotypies (24.6%) and ataxia (16.2%) were the most prevalent movement disorders, with gene- and pathway-specific movement disorder signatures extending beyond previously known associations. Notably, most patients exhibited mixed movement disorders, highlighting the phenotypic complexity of EDS. Epilepsy was diagnosed in only 66.8% of cases, suggesting that some EDS primarily manifest as movement disorders. Developmental trajectories varied by genetic aetiology. Pharmacological responses demonstrated gene- and pathway-specific treatment effects, confirming established therapeutic associations (e.g. PRRT2 variants responding to carbamazepine) and identifying previously unrecognized effects, such as exacerbation of motor symptoms with levodopa/carbidopa in GNAO1 and MECP2 variants. This study provides a detailed characterization of EDS, identifying distinct genetic, phenotypic and therapeutic patterns. The findings underscore the need for early recognition of movement disorders within epilepsy cohorts, offer immediate insights to improve anticipatory guidance and clinical management of EDS, and advocate for personalized treatment strategies. By laying the groundwork for longitudinal studies to refine genotype-phenotype correlations and establish a natural history, this work paves the way for interventional clinical trials and precision medicine approaches.

20 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FMFrancesca Magrinelli
Francesca Magrinelli
CTChristelle Tesson
Christelle Tesson
Plamena R. AngelovaPlamena R. Angelova
Plamena R. Angelova
JRJose A. Rodriguez
Jose A. Rodriguez
ASAnnarita Scardamaglia
Annarita Scardamaglia
HHHenry Houlden
Henry Houlden
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here, we identify PSMF1 as a novel gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 17 pedigrees with 24 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/PI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants impair mitochondrial membrane potential, dynamics and mitophagy, and may affect proteasomal abundance and assembly in patient-derived fibroblasts. Furthermore, Drosophila and mouse models of PSMF1 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as mechanistic contributors.

15 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFrancesca Magrinelli
Francesca Magrinelli
CTChristelle Tesson
Christelle Tesson
Plamena R. AngelovaPlamena R. Angelova
Plamena R. Angelova
JRJose A. Rodriguez
Jose A. Rodriguez
ASAnnarita Scardamaglia
Annarita Scardamaglia
HHHenry Houlden
Henry Houlden
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here we identify PSMF1 as a gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 18 pedigrees with 25 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/hPI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants may affect proteasomal abundance and assembly, and are associated with alterations of mitochondrial membrane potential, respiration, dynamics and mitophagy in patient-derived fibroblasts. Furthermore, Drosophila and mouse models of PI31 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1/hPI31 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as pathogenic contributors.

1 August 2025 in Movement Disorders
Verified
Journal Article
Open access
ASAinara Salazar‐Villacorta
Ainara Salazar‐Villacorta
ACAna Cazurro‐Gutiérrez
Ana Cazurro‐Gutiérrez
LMLucy Dunia Dougherty de Miguel
Lucy Dunia Dougherty de Miguel
JFJulia Ferrero‐Turrión
Julia Ferrero‐Turrión
AMAnna Marcé-Grau
Anna Marcé-Grau
BPBelén Pérez‐Dueñas
Belén Pérez‐Dueñas
Background: Deep brain stimulation of the globus pallidus internus (DBS‐GPi) has shown efficacy in adult patients with SGCE ‐related myoclonus dystonia. However, evidence regarding its impact in pediatric populations is limited. Objectives: The aim was to evaluate motor and non‐motor outcomes following DBS‐GPi intervention in children and adolescents with SGCE ‐MD. Methods: Ten patients (mean age 12.8 ± 3.4 years) underwent DBS‐GPi. Blinded experts rated patients with the Unified Myoclonus, Burke‐Fahn‐Marsden, Writer's cramp and Gait Dystonia rating scales. Psychiatric and quality‐of‐life outcomes were evaluated using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria and Quality of Life in Neurological Disorders. Results: Significant improvements were observed in myoclonus (68.1%), generalized dystonia (63.2%), and dystonia during writing (48.1%), walking (70.3%) and running (44.2%) after 3.8 ± 2.4 years of the surgery. Psychiatric symptoms remained stable, while quality‐of‐life assessments revealed reductions in anxiety, fatigue, and stigma ( P < 0.05). Conclusions: DBS‐GPi in children with SGCE ‐myoclonus dystonia mitigates long‐term disability, potentially enhancing academic, social, and professional prospects. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 December 2025 in Neurology Genetics
Verified
Journal Article
Open access
HSHenriette V.F. Senghor
Henriette V.F. Senghor
RRRaúl Domínguez Rubio
Raúl Domínguez Rubio
CMCarla Marco
Carla Marco
ASAinara Salazar-Villacorta
Ainara Salazar-Villacorta
APAriadna Padró-Miquel
Ariadna Padró-Miquel
PCPedro M Rodriguez Cruz
Pedro M Rodriguez Cruz
SYNE1 deficiency is an autosomal recessive disorder with a broad phenotypic spectrum, most commonly presenting as adult-onset cerebellar ataxia with or without motor neuron dysfunction. We aimed to expand this spectrum by describing the clinical and genetic findings in 2 unrelated families with early-onset motor neuron disease and virtually no cerebellar signs over time. We performed detailed clinical, neurophysiologic, and genetic studies of 2 unrelated families with juvenile amyotrophic lateral sclerosis (ALS) and biallelic variants in SYNE1. The phenotypes of both families showed onset of symptoms in childhood or adolescence, with signs of upper and lower motor neuron dysfunction in multiple territories suggestive of juvenile ALS. Patients developed progressive muscle weakness, eventually leading to respiratory distress and bulbar signs. Whole-exome sequencing identified SYNE1 biallelic truncating variants in both families: a homozygous nonsense variant, c.23131C>T (p.Gln7711*), in Family 1, and a novel homozygous splice-site variant, c.17851-1G>A, in Family 2. Notably, mild or no cerebellar manifestations were observed during the follow-up. This report highlights a novel phenotype of SYNE1 deficiency characterized by early-onset motor neuron disease and virtually no cerebellar manifestations, broadening the phenotypic spectrum of this complex neurodegenerative disease. These findings support investigating SYNE1 variants in juvenile ALS and including SYNE1 in motor neuron disease gene panels.

17 April 2026 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
JDJana Domínguez‐Carral
Jana Domínguez‐Carral
ACAna María Domínguez Cobo
Ana María Domínguez Cobo
SBSol Balsells
Sol Balsells
AAAnna Aguilar‐Ros
Anna Aguilar‐Ros
CCChu‐Ting Chang
Chu‐Ting Chang
JOJuan Darío Ortigoza‐Escobar
Juan Darío Ortigoza‐Escobar
Objective: Pathogenic variants in GNAO1 cause a spectrum of epilepsy, movement disorders, and developmental impairment. Clinical heterogeneity complicates prognosis and therapeutic development. We present the first longitudinal natural history study of GNAO1 ‐related disorders ( GNAO1 ‐RD) to delineate phenotypic trajectories. Methods: Sixty‐six individuals with GNAO1 ‐RD were included in a cross‐sectional analysis. Of these, 21 were enrolled in a prospective natural history arm (March 2021–December 2024), undergoing annual standardized evaluations with validated clinical scales to monitor phenotypic progression. Results: Our cohort exhibited broad phenotypic and severity variability. GNAO1 ‐RD severity scores ranged from 0.5 to 13. Neurodevelopmental impairment varied: 45.5% lacked head control, whereas 22.7% achieved independent walking; and 65% had no expressive language. Movement disorders were nearly universal (95.5%), with dyskinetic crises in 54.5%. Epilepsy affected 51.5%, with different seizure types. Individuals carrying recurrent variants showed consistent phenotypes and severity, supporting a genotype–phenotype correlation reinforced by molecular functional data. Molecular functional analysis for 20 of 31 missense variants correlated with severity scores. Longitudinal data from 21 patients in the natural history cohort showed overall stability or mild improvement across most functional domains. No significant deterioration was observed in global severity, motor function, cognition, or quality of life. However, severe patients experienced progressive worsening of movement disorder. Interpretation: This largest GNAO1 ‐RD cohort and first longitudinal natural history study provide insights into disease progression. GNAO1 ‐RD generally follows a non‐degenerative course, showing stability or mild improvements over time in cognition, language, adaptive skills, and motor function. Importantly, although global severity scores remained stable overall, severe cases showed cumulative functional burden driven by progressive movement disorder, rather than global neurodegeneration. Mortality occurred in a subset of patients because of complications from dyskinetic crises, infections, and epilepsy‐related events. Genotype–phenotype data and the GNAO1 ‐RD severity score support early risk stratification and personalized treatment development. ANN NEUROL 2026;100:154–170